We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+7.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$357M
AUM Growth
+$14.3M
(+4.2%)
Cap. Flow
-$378K
Cap. Flow
% of AUM
-0.11%
Top 10 Holdings %
Top 10 Hldgs %
60.48%
Holding
73
New
21
Increased
19
Reduced
16
Closed
11
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
0.8
years
Top 20 Avg Time Held Equity + Options
0.7
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Ensign Group
ENSG
|
+$7.79M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$6.69M |
| 3 |
Audentes Therapeutics, Inc
BOLD
|
+$6.13M |
| 4 |
Illumina
ILMN
|
+$5.94M |
| 5 |
Centene
CNC
|
+$4.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NUVA
NuVasive, Inc.
NUVA
|
+$14.1M |
| 2 |
Amarin Corp
AMRN
|
+$9.2M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$8.15M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
+$7.81M |
| 5 |
AERI
Aerie Pharmaceuticals
AERI
|
+$5.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.49% |
| 2 | Industrials | 9.51% |
| 3 | Financials | 4.31% |
| 4 | Miscellaneous | 1.99% |
| 5 | Real Estate | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
AKRX
51
DELISTED
Akorn Inc
AKRX
| $678K | 0.19% |
+131,640
| New | +$507K |
2019 Q2
0 quarters
|
|
|
DRNA
52
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $647K | 0.18% |
41,074
| – | – |
2018 Q2
4 quarters
|
|
|
FOMX
53
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $627K | 0.18% |
263,390
-31,270
| -11% | -$93.4K |
2018 Q1
5 quarters
|
|
54
DELISTED
Cymabay Therapeutics
CBAY
| $604K | 0.17% |
84,296
-23,000
| -21% | -$260K |
2018 Q2
4 quarters
|
|
|
ALBO
55
DELISTED
Albireo Pharma Inc
ALBO
| $581K | 0.16% |
18,029
| – | – |
2018 Q1
5 quarters
|
|
56
Savara
SVRA
$914M
| $574K | 0.16% |
+242,143
| New | +$2.15M |
2019 Q2
0 quarters
|
|
57
DELISTED
scPharmaceuticals
SCPH
| $556K | 0.16% |
+174,297
| New | +$570K |
2019 Q2
0 quarters
|
|
|
PFNX
58
DELISTED
Pfenex Inc.
PFNX
| $546K | 0.15% |
80,968
+5,268
| +7% | +$33.7K |
2019 Q1
1 quarter
|
|
|
OTIC
59
DELISTED
Otonomy, Inc.
OTIC
| $535K | 0.15% |
194,429
+14,329
| +8% | +$38.2K |
2019 Q1
1 quarter
|
|
60
CALL
BioCryst Pharmaceuticals
BCRX
$1.99B
| $386K | 0.11% |
+101,800
| New | +$613K |
2019 Q2
0 quarters
|
|
|
KRSA
61
Korsana Biosciences, Inc. Common Stock
KRSA
$1.47B
| $217K | 0.06% |
+135
| New | +$267K |
2019 Q2
0 quarters
|
|
62
Neurogene
NGNE
$465M
| $174K | 0.05% |
3,686
| – | – |
2018 Q4
2 quarters
|
|
63
Coherus Oncology
CHRS
$153M
| – | – |
-120,036
| Closed | -$1.64M | – |
|
64
CRISPR Therapeutics
CRSP
$4.76B
| – | – |
-42,400
| Closed | -$1.51M | – |
|
65
Ironwood Pharmaceuticals
IRWD
$578M
| – | – |
-233,667
| Closed | -$2.65M | – |
|
66
PUT
Novavax
NVAX
$1.86B
| – | – |
-7,255
| Closed | -$79.9K | – |
|
67
Option Care Health
OPCH
$4.67B
| – | – |
-30,753
| Closed | -$246K | – |
|
|
ICPT
68
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
-43,800
| Closed | -$4.9M | – |
|
|
CNCE
69
CALL
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| – | – |
-2,300
| Closed | -$27.8K | – |
|
|
CNCE
70
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| – | – |
-47,154
| Closed | -$569K | – |
|
|
ABMD
71
DELISTED
Abiomed Inc
ABMD
| – | – |
-27,339
| Closed | -$7.81M | – |
|
|
AERI
72
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-114,779
| Closed | -$5.45M | – |
|
73
DELISTED
Array Biopharma Inc
ARRY
| – | – |
-214,112
| Closed | -$5.22M | – |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q2 2019 Portfolio in Review
As of Q2 2019, Eversept Partners held 73 positions worth $357M, up 4.2% from $343M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Eversept Partners's Q2 2019 filing shows 21 new, 19 increased, 16 reduced and 11 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M. The largest sale was NuVasive, Inc., an estimated $14.1M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Industrials and Financials.
- Eversept Partners's largest Q2 2019 buy was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M.
- Eversept Partners added most to The Ensign Group in Q2 2019, an estimated $7.79M increase.
- Eversept Partners's biggest Q2 2019 reduction was NuVasive, Inc., cutting an estimated $14.1M.
- Eversept Partners fully exited Abiomed Inc in Q2 2019, selling an estimated $7.81M.
- Eversept Partners's ten largest holdings make up 60% of its $357M portfolio in Q2 2019.
- Eversept Partners opened 21 new positions and closed 11 in Q2 2019.
- Eversept Partners's portfolio value rose 4.2% quarter-over-quarter to $357M.
Based on Eversept Partners's 13F filing for Q2 2019, filed 13 Aug 2019.